Ruoyun Wang

Ruoyun Wang

Auto-generated profile, based on publicly available information

Ruoyun Wang

Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2022 in JMIR Formative Research
Verified
Journal Article
Open access
GNGinger Nicol
Ginger Nicol
RWRuoyun Wang
Ruoyun Wang
SGSharon Graham
Sharon Graham
SDSherry Dodd
Sherry Dodd
JGJane Garbutt
Jane Garbutt
Background: Symptoms of depression and anxiety, suicidal ideation, and self-harm have escalated among adolescents to crisis levels during the COVID-19 pandemic. As a result, primary care providers (PCPs) are often called on to provide first-line care for these youth. Digital health interventions can extend mental health specialty care, but few are evidence based. We evaluated the feasibility of delivering an evidence-based mobile health (mHealth) app with an embedded conversational agent to deliver cognitive behavioral therapy (CBT) to symptomatic adolescents presenting in primary care settings during the pandemic. Objective: In this 12-week pilot study, we evaluated the feasibility of delivering the app-based intervention to adolescents aged 13 to 17 years with moderate depressive symptoms who were treated in a practice-based research network (PBRN) of academically affiliated primary care clinics. We also obtained preliminary estimates of app acceptability, effectiveness, and usability. Methods: This small, pilot randomized controlled trial (RCT) evaluated depressive symptom severity in adolescents randomized to the app or to a wait list control condition. The primary end point was depression severity at 4-weeks, measured by the 9-item Patient Health Questionnaire (PHQ-9). Data on acceptability, feasibility, and usability were collected from adolescents and their parent or legal guardian. Qualitative interviews were conducted with 13 PCPs from 11 PBRN clinics to identify facilitators and barriers to incorporating mental health apps in treatment planning for adolescents with depression and anxiety. Results: The pilot randomized 18 participants to the app (n=10, 56%) or to a wait list control condition (n=8, 44%); 17 participants were included in the analysis, and 1 became ineligible upon chart review due to lack of eligibility based on documented diagnosis. The overall sample was predominantly female (15/17, 88%), White (15/17, 88%), and privately insured (15/17, 88%). Mean PHQ-9 scores at 4 weeks decreased by 3.3 points in the active treatment group (representing a shift in mean depression score from moderate to mild symptom severity categories) and 2 points in the wait list control group (no shift in symptom severity category). Teen- and parent-reported usability, feasibility, and acceptability of the app was high. PCPs reported preference for introducing mHealth interventions like the one in this study early in the course of care for individuals presenting with mild or moderate symptoms. Conclusions: In this small study, we demonstrated the feasibility, acceptability, usability, and safety of using a CBT-based chatbot for adolescents presenting with moderate depressive symptoms in a network of PBRN-based primary care clinics. This pilot study could not establish effectiveness, but our results suggest that further study in a larger pediatric population is warranted. Future study inclusive of rural, socioeconomically disadvantaged, and underrepresented communities is needed to establish generalizability of effectiveness and identify implementation-related adaptations needed to promote broader uptake in pediatric primary care. Trial Registration: ClinicalTrials.gov NCT04603053; https://clinicaltrials.gov/ct2/show/NCT04603053

7 July 2021 in Pediatrics
Verified
Journal Article
Open access
PDF file
EHElizabeth Harrison
Elizabeth Harrison
JGJane Garbutt
Jane Garbutt
RSRandall Sterkel
Randall Sterkel
SDSherry Dodd
Sherry Dodd
RWRuoyun Wang
Ruoyun Wang
KPKatie Plax
Katie Plax
The St Louis Regional Pediatric Learning Collaborative of pediatric primary care providers and infectious diseases specialists formed in March 2020 to address the needs of children and families during the coronavirus disease 2019 (COVID-19) pandemic. More than 400 pediatric primary care providers participated, using a listserv to discuss care and organize webinars to provide updates on local and national data and plan next steps. To inform local decision-making about care and testing for severe acute respiratory syndrome coronavirus 2, 95 providers from 26 practices partnered with the local practice-based research network to rapidly collect and share data about children with COVID-19–like symptoms. Of 2162 children tested for severe acute respiratory syndrome coronavirus 2, 9% had positive test results. Test result positivity was 33% if a patient was exposed to a confirmed case of COVID-19 and 4% if they had COVID-19–like symptoms and no exposure. School or day care attendance was associated with lower rates of positive test results. Although not originally planned, these findings drove local advocacy efforts by the Collaborative for increased access to testing and contact tracing and safe in-person school. Members communicated directly and collectively with local politicians, provided advice and resources for school boards and superintendent groups, and appeared on various media platforms. In these efforts, they shared local data, highlighting the lower rate of positive test results for children in school to support the idea that schools could be safely open. Outreach from trusted pediatricians sharing prospective, timely, local data sustained in-person school for some districts and aided in future in-person openings for other school districts.

2 February 2026 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RWRuoyun Wang
Ruoyun Wang
LLLei Liu
Lei Liu
SDSherry Dodd
Sherry Dodd
SGSharon Graham
Sharon Graham
SRShannon Rook
Shannon Rook
AKAllison A. King
Allison A. King
Importance: Human papillomavirus (HPV) vaccination prevents multiple cancers, yet vaccination rates by the recommended age remain well below national goals. Objective: To evaluate the effectiveness of a multicomponent strategy in increasing HPV vaccination rates in primary care settings by 13 years of age. Design, Setting, and Participants: This cluster randomized clinical trial with a parallel-group design and 1:1 allocation was conducted at 20 pediatrics primary care practices from a practice-based research network in the St Louis, Missouri, metropolitan area by clinicians delivering routine well-child visits within participating practices. The intervention was implemented over 24 months (July 1, 2020, to September 30, 2022) with follow-up at 36 months (July 1, 2022, to September 30, 2023; 12 months after the intervention). Baseline characteristics were assessed using 2019 data. Interventions: (1) Practice facilitation by a trained external facilitator, (2) audit and feedback of HPV vaccination rates, (3) HPV vaccination education, and (4) announcement-style communication strategy. Main Outcomes and Measures: The primary outcomes were the proportion of patients who received the first HPV vaccine (initiation) and completed the series (completion) by 13 years of age, assessed at 24 months. Enduring effect was assessed at 36 months. Data were analyzed based on the intention-to-treat principle. Results: A total of 86 clinicians participated (40 control and 46 intervention; 65 women [75.6%]). Most were physicians (67 [77.9%]) and median time in practice was 18 years (IQR, 10-24 years). The intervention group had a higher percentage of privately insured patients than the control group (1562 of 1727 [90.4%] vs 717 of 1371 [52.3%]). At 24 months, HPV vaccination initiation rates were 80.1% (1723 of 2151) in the intervention group vs 75.5% (1219 of 1615) in the control group; completion rates were 52.8% (1135 of 2151) in the intervention group vs 50.1% (809 of 1615) in the control group. At 36 months, initiation rates were 82.0% (1812 of 2211) in the intervention group vs 74.6% (1052 of 1410) in the control group; completion rates were 57.8% (1279 of 2211) in the intervention group vs 49.9% (703 of 1410) in the control group. Fully adjusted models showed no differences for vaccination initiation (24 months: odds ratio [OR], 1.15 [95% CI, 0.78-1.70]; 36 months: OR, 1.42 [95% CI, 0.96-2.11]) or completion (24 months: OR, 0.96 [95% CI, 0.72-1.29]; 36 months: OR, 1.24 [95% CI, 0.92-1.67]), although intervention effects for initiation increased significantly over time ( P = .04). Conclusions and Relevance: In this cluster randomized clinical trial of a multicomponent intervention in 20 practices, HPV vaccination rates by 13 years of age were not significantly different between groups, although intervention effects increased significantly over time for initiation of vaccination. System-focused interventions may require extended evaluation periods to demonstrate measurable improvements. Trial Registration: ClinicalTrials.gov Identifier: NCT04180462